French antibody specialist Adcytherix closed a sizable Series A (reported at about €105 million / US$122 million) to advance its lead antibody‑drug conjugate into first‑in‑human studies. The funding will support IND‑enabling studies and early clinical development aimed at targeting hard‑to‑treat cancers with next‑generation ADC designs. Investors emphasized the company’s preclinical payload‑linker optimization and translational biomarker strategy. Adcytherix’s raise underscores continuing investor interest in ADCs that promise improved therapeutic windows and manufacturability. Watch for IND submissions, CMC updates, and early safety/PK data that will determine whether the preclinical promise translates to clinical activity and differentiates the program in a crowded ADC landscape.